Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated the efficacy and safety of evolocumab by diabetes status and the effect of evolocumab on gl...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet. Diabetes & endocrinology Vol. 5; no. 12; p. 941
Main Authors:	Sabatine, Marc S, Leiter, Lawrence A, Wiviott, Stephen D, Giugliano, Robert P, Deedwania, Prakash, De Ferrari, Gaetano M, Murphy, Sabina A, Kuder, Julia F, Gouni-Berthold, Ioanna, Lewis, Basil S, Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R
Format:	Journal Article
Language:	English
Published:	England 01.12.2017
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Blood Glucose - drug effects Blood Glucose - metabolism Cardiovascular Diseases - blood Cardiovascular Diseases - chemically induced Cardiovascular Diseases - prevention & control Diabetes Mellitus - blood Diabetes Mellitus - chemically induced Diabetes Mellitus - drug therapy Double-Blind Method Female Follow-Up Studies Humans Male Middle Aged Proprotein Convertase 9 - antagonists & inhibitors Risk Factors Treatment Outcome
ISSN:	2213-8595, 2213-8595
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!